Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of heterologous and homologous COVID-19 vaccine schedules
ISRCTN69254139Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Feb 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
01
Overview
Phase 2, randomised, open-label trial of ChAdOx1 nCoV-19 and tozinameran in coronavirus disease 2019 (COVID-19) (8 arms), sponsored by University of Oxford. Primary endpoint: Anti-spike immunoglobulin response at day 56 in seronegative participants boosted at day 28. Started Feb 2021; status: completed.
02
Drugs
ChAdOx1 nCoV-19tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ISRCTN69254139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN69254139.